India has denied speculation of a "witch-hunt" targeting the local physicians who were involved in the controversial superbug study that was published in Lancet Infectious Diseases last month.

India's Drugs Controller General of India,.....

Astellas's US-based anticancer antibody subsidiary, Agensys, has begun clinical trials with an antibody-drug conjugate (ADC) for metastatic renal cancer, building on an alliance with Seattle Genetics which was expanded last year.

The ADC,.....

Taiwan's ScinoPharm is to make an investment in the US firm Tanvex Biologics, with the intention of building up joint capacity for the manufacture of biosimilars in the US market.

The investment will take the form of assets,.....

Forbion Capital Partners, the Netherlands-based life sciences-focused venture capitalist, has defied the moribund capital market by raising €190 million for two new funds, FCF I Co-Invest Fund and FCF II. As with Forbion's first fund, FCF I, the.....

We are delighted to announce the shortlist for the 6th Annual Scrip Awards. This year we were impressed with the calibre of the entries and we believe the shortlist, chosen by our judging panel of 19 industry experts, reflects the ground-breaking work.....

An editorial in New England Journal Medicine – penned to coincide with the

We are delighted to announce the shortlist for the 6th Annual Scrip Awards. This year we were impressed with the calibre of the entries and we believe the shortlist, chosen by our judging panel of 19 industry experts, reflects the.....

You are a drug company looking for a new candidate to treat obesity. You hear about a tribe in Africa using a certain plant to suppress hunger when they go on long hunting trips. Sounds like there may be a potential blockbuster for those.....

Greece's pricing committee has delayed publishing a price bulletin which was going to set out the prices for all pharmaceutical products available on the market.

The new price bulletin (for all pharmaceutical products) had been due.....

The US FDA has warned healthcare professionals that Pfizer's antibacterial Tygacil (tigecycline) is associated with an increased risk of mortality compared with other drugs that can be used to treat various serious complications. "The increased risk.....

In a bid to beef up its research pipeline Ipsen, the French speciality pharma company, is paying Santhera Pharmaceuticals €13 million up front for the rights to its adrenergic alpha-2 receptor antagonist fipamezole outside North.....

The NHS in the UK could be could be wasting £100 million on medicines that are never consumed, suggests a study to be presented at the Royal Pharmaceutical Society of Great Britain's annual conference in London next week.

Pharmacist Elmarie.....

There is less than a month to go before money from England's new £50 million cancer drugs fund becomes available, but pharmaceutical companies are still in the dark about how to use the fund to get their drugs to patients.

And after another.....

Roche is mulling over plans to slash its operating costs to cope with "mounting pressures to curb healthcare costs" and to deal with a spate of recent setbacks in its late-stage programmes. It said it would review and analyse its.....

Forbion Capital Partners, the Netherlands-based life sciences-focused venture capitalist, has defied the moribund capital market by raising €190 million for two new funds, FCF I Co-Invest Fund and FCF II. As with Forbion's first fund, FCF I, the.....

ThromboGenic's microplasmin met its primary endpoint – resolution of vitromacular adhesion (VMA) – in patients with the eye disease. The study results, presented at the American Society of Retina Specialists (ASRS) meeting this.....

Takeda has acquired exclusive rights in the US, Canada and Mexico to Orexigen Therapeutics' obesity drug Contrave (bupropion SR plus naltrexone SR).

Japan's largest pharma firm will develop and commercialise the combination product.....

Eisai has begun a clinical trial with a novel monoclonal antibody for Alzheimer's disease, which the firm says is the first potential therapy of its type which selectively binds to and eliminates the amyloid-beta aggregates which are linked to the.....

Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which it will develop initially for pancreatic cancer.

The Japanese firm will pay.....

Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two companies did not disclose the financial terms of the acquisition, though Pfizer will make an.....